Objective: Recovery of motor function after moderate to severe stroke is challenging given the paucity of therapeutic choices. Here we show an effective treatment with a new combination of drugs which protect neuronal mitochondria from oxidative stress, inflammation, and subsequent apoptosis; decrease excitotoxicity, and indirectly increase brain derived neurotrophic factor (BDNF), insulin growth factor-1 (IGF-1), transforming growth factor- ? (TGF-?), etc. Method: Treatment and patients; The new combination consists of medications approved for human use in multiple pathologies: glutathione, oxytocin, dimethylsulfoxide (DMSO), deproteinated veal serum (Actovegin), vitamins C, B1, B6, B12, which were administered intravenously in an open-label, pilot study. Motor function was evaluated in 15 consecutive hemiplegic patients with the National Institutes of Health Stroke Scale (NIHSS) initially and at 1 month after administering first intravenous treatment, and subsequently. Results: At 1 month post-treatment evaluation, when treatment was administered at days 10 - 35 post-stroke, motor improvement (n=5, mean ?NIHSS score = - 3.6), was significantly better than when administered at 35-100 days post-stroke (n=6, mean ?NIHSS = - 0.83), and virtually no improvements when given after 3 months post-stroke (n=4,101-365 days, mean ?NIHSS = 0). Motor improvements at 2 and 3 months post-treatment were seen only in the group treated at 10-35 days post-stroke, with one complete recovery at 6 months. Conclusion: excellent results were obtained in subacute stroke patients with hemorrhagic transformation of ischemic stroke, recommending it as a much needed addition to the current treatment options for stroke and more ample clinical trials. Keywords: stroke treatment, post-stroke recovery, hemiplegia treatment, motor recovery in stroke, hemorrhagic transformation
Corresponding Author: Stancioiu F.